Loading
Life sciences · Journal article
Advanced Healthcare Materials · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT The increasing global burden of severe diseases, such as cancers, cardiovascular and neurodegenerative disorders, highlights the urgent need for advanced diagnostic and therapeutic agents. Although techniques like computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and chemotherapy show promise, their effectiveness is frequently constrained by the inherent drawbacks of conventional agents, such as poor solubility, low stability, and lack of targeting ability, as well as physiological barriers like the blood‐brain barrier (BBB), which limit bioavailability and induce systemic toxicity. Mesoporous silica nanoparticles (MSNs) have emerged as promising platforms to overcome these challenges, offering high surface area, tunable pore size, and facile surface functionalization for efficient cargo loading. Therefore, in this work, the recent advances in the synthesis, structural control, and functional design of MSNs‐based composites are systematically reviewed, with a focus on their biomedical applications in diagnosis (e.g., fluorescence imaging (FLI)/MRI/PET), therapy (e.g., chemo‐, dynamic, thermal, and gas therapy), and tissue engineering. Key strategies for performance optimization and structure‐property relationships are discussed in depth. Finally, we delineate prevailing challenges and future directions for the clinical translation of MSNs‐based nanomaterials, providing an integrated perspective to guide their rational design and biomedical implementation.